Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going
Executive Summary
Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.
You may also be interested in...
Califf: More Learning Necessary During Generic Drug Lifecycle
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.
BsUFA III Talks Could Move Cloud-Platform Goals Forward
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.